Steven M. Goldman is Director at Dova Pharmaceuticals, Inc. (DOVA). They have made 8 open-market trades across 2 companies since 2013, most recently 2019-11-12.
CIK 0001568216
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $1.9M since 2013, never a sale. Across 8 scored buys the stock is down 7.9% at ninety days, and 10.9 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 13% | 75% | 50% |
| Avg Move | -5.5% | -3.7% | -7.9% |
| Alpha | -2.9% | -5.0% | -10.9% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DOVA | BUY | 2018-06-21 | 2018-06-25 | $30.22 | $151K | -13.5% | -29.7% | -28.8% |
| DOVA | BUY | 2018-06-05 | 2018-06-06 | $26.41 | $396K | +1.6% | -2.2% | -22.4% |
| DOVA | BUY | 2017-08-15 | 2017-08-17 | $22.23 | $897K | -4.6% | +0.1% | -7.0% |
| DOVA | BUY | 2017-07-05 | 2017-08-17 | $19.64 | $98K | -4.6% | +0.1% | -7.0% |
| CNOB | BUY | 2014-02-04 | 2014-02-06 | $44.43 | $111K | -5.8% | +0.4% | +0.4% |
| CNOB | BUY | 2014-01-31 | 2014-02-04 | $45.75 | $46K | -5.8% | +0.4% | +0.4% |
| CNOB | BUY | 2013-05-03 | 2013-05-06 | $29.35 | $161K | -5.8% | +0.4% | +0.4% |
| CNOB | BUY | 2013-02-12 | 2013-02-13 | $28.00 | $56K | -5.8% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.